Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker

MLA

Afd Pharmaceutics, et al. Acute Lymphoblastic Leukaemia Patients Treated with PEGasparaginase Develop Antibodies to PEG and the Succinate Linker. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1292930432&authtype=sso&custid=ns315887.

APA

Afd Pharmaceutics, Pharmaceutics, Kloos, R., van der Sluis, I. M., Mastrobattista, E., Hennink, W., Pieters, R., & Verhoef, J.-J. (2020). Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.

Chicago

Afd Pharmaceutics, Pharmaceutics, Robin Kloos, Inge M van der Sluis, Enrico Mastrobattista, Wim Hennink, Rob Pieters, and Jan-Jaap Verhoef. 2020. “Acute Lymphoblastic Leukaemia Patients Treated with PEGasparaginase Develop Antibodies to PEG and the Succinate Linker.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1292930432&authtype=sso&custid=ns315887.